BACKGROUND: According to the very limited @entity5 registry, incidence and mortality rates for female @entity0 in China are regarded to be increasing especially in the metropolitan areas. Representative data on the @entity0 profile of Chinese @entity1 and its time trend over years are relatively rare. The aims of the current study are to illustrate the @entity0 profile of Chinese @entity1 in time span and to explore the current treatment approaches to female @entity0 . METHODS: This was a hospital-based nation-wide and multi-center retrospective study of female primary @entity0 cases. China was divided into 7 regions according to the geographic distribution; from each region, one tertiary hospital was selected. With the exception of January and February, one month was randomly selected to represent each year from year 1999 to 2008 at every hospital. All inpatient cases within the selected month were reviewed and related information was collected based on the designed @entity7495 ( @entity7495 ). The @entity5 Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS) was the leading hospital in this study. RESULTS: Four-thousand two-hundred and eleven cases were randomly selected from the total pool of 45,200 @entity1 and were included in the analysis. The mean age at diagnosis was 48.7 years (s.d. = 10.5 yrs) and @entity0 peaked in age group 40-49 yrs (38.6%). The most common subtype was infiltrating @entity513 (86.5%). Clinical stage I _ II accounted for 60.6% of 4,211 @entity1 . Three-thousand five-hundred and thirty-four cases had @entity172 receptor (ER) and @entity1871 receptor (PR) tests, among them, 47.9% were positive for both. Two-thousand eight-hundred and forty-nine cases had @entity1 @entity1722 ( @entity1722 ) tests, 25.8% of them were @entity1722 positive. Among all treatment options, surgery (96.9% (4,078/4,211)) was predominant, followed by chemotherapy (81.4% (3,428/4,211). Much less @entity1 underwent radiotherapy (22.6% (952/4,211)) and endocrine therapy (38.0% (1,599/4,211)). CONCLUSIONS: The younger age of @entity0 onset among Chinese @entity1 and more advanced @entity5 stages pose a great challenge. Adjuvant therapy, especially radiotherapy and endocrine therapy are of great unmet needs.

A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female XXXX in China.

@entity1 :: ('9606', 'Species') :: ['women', 'human', 'patients'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer'] @entity513 :: ('MESH:D044584', 'Disease') :: ['ductal carcinoma'] @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['progestin'] @entity7495 :: ('MESH:D017825', 'Disease') :: ['CRF', 'case report form'] @entity1722 :: ('2064', 'Gene') :: ['HER-2', 'epidermal growth factor receptor 2']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
